Evidence map›Paper›PMID 31852329›Full record

ArticleLeukemia & lymphoma2020

Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia.

Joseph Lipscomb, Jeffrey M Switchenko, Christopher R Flowers, Theresa W Gillespie, Pascale M Wortley, A Rana Bayakly, Lyn Almon, Robyn Fernando, Kevin C Ward

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Joseph LipscombDepartment of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Jeffrey M SwitchenkoWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Christopher R FlowersDepartment of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Theresa W GillespieWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Pascale M WortleyGeorgia Department of Public Health, Emory University, Atlanta, GA, USA.
A Rana BayaklyGeorgia Department of Public Health, Emory University, Atlanta, GA, USA.
Lyn AlmonGeorgia Center for Cancer Statistics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Robyn FernandoDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Kevin C WardWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Emory University · USGeorgia Department of Public Health · USThe University of Texas MD Anderson Cancer Center · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
GEORGIA COMPREHENSIVE CANCER CONTROL PROGRAMU58DP003875 · DP · GEORGIA DIVISION OF PUBLIC HEALTH · PI O'CONNOR, JEAN CATHERINE · 2012 to 2014
$15.9M
NCCDPHP CDC HHS U58 DP003875NCI NIH HHS HHSN261201000025CNCI NIH HHS HHSN261201800003CNCI NIH HHS P30 CA138292NIAID NIH HHS P30 AI050409
6 · The paper itself

Abstract

We conducted a population-based study of biologic, clinical, and sociodemographic factors associated with receipt of multi-agent systemic therapy (MAST) by people living with HIV (PLWH) who were diagnosed with non-Hodgkin lymphoma (NHL). Building on recent registry-based analyses, we linked records from the Georgia Cancer Registry, Georgia HIV/AIDS Surveillance Registry, and the Georgia Hospital Discharge Database to identify 328 PLWH adults (age ≥ 18) diagnosed with NHL within 2004-2012. Through logistic regression modeling, we examined factors associated with patients receiving MAST for NHL. Robust predictors included CD4 count ≥200 cells/mm

Indexed as

Biological ProductsHIV InfectionsLymphoma, AIDS-RelatedLymphoma, Non-HodgkinSexual and Gender MinoritiesAdultCD4 Lymphocyte CountGeorgiaHomosexuality, MaleHumansMaleBiological ProductsHIV/AIDSmulti-agent systemic therapyNon-Hodgson lymphomastandard-of-care therapy

Identifiers

PMID31852329
PMCPMC7082188
OpenAlexW2995924672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.